JAMA Medical News June 2024 Medical News Summary
Jun 28, 2024
Topics discussed in the podcast include the resurgence of syphilis in the US due to various factors, the potential shift in statin eligibility with a new CVD risk calculator, challenges in syphilis prophylaxis with doxycycline, alarming increase in congenital syphilis cases, updated recommendations for screening in pregnancy, and the introduction of the PREVENT calculator for personalized statin recommendations based on health factors and social deprivation.
AI Snips
Chapters
Transcript
Episode notes
Surge in Syphilis Cases
- Syphilis rates in the US have surged dramatically from 6,000 cases in 2000 to over 203,000 recently.
- Multiple factors fuel this, including testing challenges, treatment shortages, and risky behaviors linked to substance use.
Doxycycline for Syphilis Prevention
- CDC recommends doxycycline post-exposure prophylaxis within 72 hours after sex to reduce syphilis risk in men who have sex with men and transgender women.
- Effectiveness in cisgender women is unclear, possibly due to adherence issues in trials, warranting further research.
Rising Congenital Syphilis Rates
- Congenital syphilis cases have risen sharply to nearly 3,800 in 2022, with a 31% increase from 2021.
- It is preventable through maternal screening and treatment, prompting updated ACOG recommendations for triple screening during pregnancy.